[1]王帅,张诗珩,张志敏,等.CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究[J].第三军医大学学报,2018,40(10):862-867.
 WANG Shuai,ZHANG Shiheng,ZHANG Zhimin,et al.CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways [J].J Third Mil Med Univ,2018,40(10):862-867.
点击复制

CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第10期
页码:
862-867
栏目:
基础医学
出版日期:
2018-05-30

文章信息/Info

Title:
CD151 inhibits brain metastasis of non-small cell lung cancer by regulating epithelial-mesenchymal transition and stemness pathways 
作者:
王帅 张诗珩张志敏杨镇洲
陆军军医大学(第三军医大学)第三附属医院(野战外科研究所)肿瘤中心
Author(s):
WANG Shuai ZHANG Shiheng ZHANG Zhimin YANG Zhenzhou

Cancer Center, Institute of Surgery Research, Third Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, 400042, China

关键词:
CD151非小细胞肺癌脑转移预测因子
Keywords:
CD151 non-small cell lung cancer brain metastases predictive factor
分类号:
R73.37;R730.23;R734.2
文献标志码:
A
摘要:

目的    探讨四跨膜蛋白CD151在肺癌脑转移中的预测作用及相关分子通路机制。方法    收集2010年12月至2015年6月本中心160例非小细胞肺癌(nonsmall cell lung cancer, NSCLC)患者临床资料,其中脑转移患者88例,无脑转移患者72例,采用免疫组织化学方法检测CD151在肺癌组织的表达,并运用Spearman分析CD151表达与脑转移相关性。再选择人NSCLC细胞株HCC827,应用siRNA干扰、Western blot、划痕和Transwell实验检测敲低CD151表达对细胞增殖、迁移状况以及上皮间质转化(EMT)、干性通路相关蛋白表达的影响。结果   相对于无脑转移患者,NSCLC脑转移患者肺癌组织CD151表达显著增加(P=0.012),Spearman分析表明CD151高表达与脑转移呈正相关(r=0.478, P=0.004)。通过siRNA敲低CD151可上调Ecadherin表达,并下调Vimentin、SOX2、CD44和CD133表达,同时降低HCC827细胞增殖(P=0.026)与迁移能力(P=0.032)。结论    CD151可能通过调控EMT、干性通路相关蛋白表达影响NSCLC细胞的增殖、迁移,CD151可能是NSCLC脑转移的潜在预测因子。

Abstract:

Objective    To investigate the value of CD151 for predicting brain metastasis of lung cancer and explore its role in promoting lung cancer metastasis and the associated signaling pathways. Methods    A total of 160 patients with non-small cell lung cancer (NSCLC) admitted in our center between December, 2010 and June, 2015 were enrolled in this study, including 88 patients with and 72 without brain metastases. CD151 expression in the lung cancer tissues was examined using immunohistochemistry and its correlation with brain metastasis was analyzed. In the in vitro experiment with human NSCLC cell line (HCC827 cells), RNA interference technique, scratch-wound assay, Transwell assay and Western blotting were used to clarify the role of CD151 in regulating cell proliferation, migration, epithelial-mesenchymal transition, and expressions of proteins in the stemness pathways. Results    Compared with those without brain metastasis, the patients with brain metastasis of NSCLC showed significantly upregulated CD151 expression in the lung cancer tissues (P=0.012). Spearman correlation analysis showed that a high expression of CD151 was positively correlated with brain metastasis of NSCLC (r=0.478, P=0.004). HCC827 cells with CD151 knockdown mediated by a small interfering RNA showed obviously suppressed cell proliferation (P=0.026) and metastasis (P=0.032), up-regulated expression of E-cadherin and down-regulated expression of vimentin, SOX2, CD44 and CD133. Conclusion    CD151 promotes the proliferation and migration of NSCLC cells possibly by regulating the protein expression associated with epithelial-mesenchymal transition and stemness pathways, suggesting its value as a potential biomarker for predicting brain metastases of lung cancer.

参考文献/References:

[1]CHEN W, ZHENG R, BAADE P D. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[2]JEMAL A, CENTER M M, DESANTISC. Global patterns of cancer incidence and mortality rates and trends[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(8): 1893-1907. DOI: 10.1158/1055-9965.
[3]BROWN T, PILKINGTON G, BAGUST A, et al. Clinical effectiveness and cost-effectiveness of firstline chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer: a systematic review and economic evaluation[J]. Health Technol Assess, 2013, 17(31): 1-278. DOI: 10.3310/hta17310.
[4]SPIRO S G, TANNER N T, SILVESTRI G A, et al.Lungcancer: progress in diagnosis, staging andtherapy[J]. Respirology, 2010, 15(1): 44-50. DOI: 10.1111/j.1440-1843.2009.01674.x.
[5]KAWAHARA M, ATAGI S, KOMUTA K, et al. Carboplatin plus either docetaxel or paclitaxel for Japanese patients with advanced nonsmall cell lung cancer[J]. Anticancer Res, 2013, 33(10): 4631-4637. DOI:0.1371/journal.pone.0111475.
[6]TATAR Z, THIVAT E, PLANCHAT E, et al. Temozolomide and unusual indications: review of literature[J]. Cancer Treat Rev, 2013, 39(2): 125-135. DOI: 10.1016/j.ctrv.2012.06.002.
[7]LIU WJ, ZENG XT, QIN HF, et al. Whole brain radiotherapy plus chemotherapy in the treatment of brain metastases from lung cancer: a metaanalysis of 19 randomized controlled trails[J]. Asian Pac J Cancer Prev, 2012, 13(7): 3253-3258. DOI: 10.7314/APJCP.2012.13.7.3253.
[8]WANG H X, LIQ, SHARMAC, et al. Tetraspanin protein contributions to cancer[J]. Biochem Soc Trans, 2011, 39(2): 547-552. DOI: 10.1042/BST0390547.
[9]GHELDOF A, BERX G. Cadherins and epithelial-to-mesenchymaltransition[J]. Prog Mol Biol Transl Sci. 2013, 116: 317-336. DOI: 10.1016/B978-0-12-394311-8.00014-5.
[10]THIERY J P, ACLOQUE H, HUANG RY J, et al. Epithelialmesenchymal transitions in development and disease[J]. Cell, 2009, 139(5): 871-890. DOI: 10.1016/j.cell.2009.11.007.
[11]MEDEMA J P. Cancer stem cells: the challenges ahead[J]. Nat Cell Biol, 2013, 15(4): 338-344. DOI: 10.1038/ncb2717.
[12]李科, 洪志鹏, 沈丽达, 等. CD151及整合素α整合素蛋白在非小细胞肺癌中的表达及意义[J]. 中国全科医学, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.
LI K, HONG Z P, SHEN L D, et al. CD151 and integrin α3β1 expression in nonsmall cell lung cancer[J]. Chin Gen Prac, 2014, 17(5): 531-535. DOI: 10.3969/j.issn.1007-9572.

相似文献/References:

[1]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(10):2039.
[2]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(10):2060.
[3]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(10):2063.
[4]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[5]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[6]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(10):1913.
[7]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(10):1699.
[8]高娟,饶进军,吴少瑜,等.丁酸钠与顺铂联用对非小细胞性肺癌细胞生长的抑制作用[J].第三军医大学学报,2007,29(11):1066.
 GAO Juan,RAO Jin-jun,WU Shao-yu,et al.Combination of sodium butyrate and cisplatin has antiproliferative effects on non-small lung cancer cell line[J].J Third Mil Med Univ,2007,29(10):1066.
[9]郑顺利,杨庆生,马小红.非小细胞肺癌患者纵隔淋巴结和外周血中MUC1基因的检测及意义[J].第三军医大学学报,2006,28(24):2472.
[10]张云嵩,范士志,王东,等.APE1在非小细胞肺癌中的表达特点及其与预后的关系[J].第三军医大学学报,2007,29(09):776.
 ZHANG Yun-song,FAN Shi-zhi,WANG Dong,et al.APE1 expression and its correlation with prognosis in non-small cell lung cancer[J].J Third Mil Med Univ,2007,29(10):776.

更新日期/Last Update: 2018-05-29